A switch in enantiomer preference between mitochondrial F1F0-ATPase chemotypes

被引：10
|
作者：
Bisaha, SN
Malley, MF
Pudzianowski, A
Monshizadegan, H
Wang, P
Madsen, CS
Gougoutas, JZ
Stein, PD
机构：
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Solid State Struct, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Comp Aided Drug Design, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Cardiovasc Biol, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 11期
关键词：
mitochondrial ATPase; acylguanidine; chiral synthesis;
D O I：
10.1016/j.bmcl.2005.03.115
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The preferred absolute configuration of two series of F1F0-ATP synthase inhibitors was determined. Although the configuration of the active enantiomer in each series is different, each series presents the same 'triaryl' pharmacophore to the enzyme binding site. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2749 / 2751
页数：3
相关论文
共 50 条
  • [1] Modifiers of the oligomycin sensitivity of the mitochondrial F1F0-ATPase
    Pagliarani, Alessandra
    Nesci, Salvatore
    Ventrella, Vittoria
    MITOCHONDRION, 2013, 13 (04) : 312 - 319
  • [2] The IF1 inhibitor protein of the mitochondrial F1F0-ATPase
    Green, DW
    Grover, GJ
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2000, 1458 (2-3): : 343 - 355
  • [3] Myocardial ischemic preconditioning and mitochondrial F1F0-ATPase activity
    Bosetti, F
    Yu, GY
    Zucchi, R
    Ronca-Testoni, S
    Solaini, G
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2000, 215 (1-2) : 31 - 37
  • [4] Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase
    Johnson, Kathryn M.
    Cleary, Joanne
    Fierke, Carol A.
    Opipari, Anthony W., Jr.
    Glick, Gary D.
    ACS CHEMICAL BIOLOGY, 2006, 1 (05) : 304 - 308
  • [5] Myocardial ischemic preconditioning and mitochondrial F1F0-ATPase activity
    Francesca Bosetti
    Gongyuan Yu
    Riccardo Zucchi
    Simonetta Ronca-Testoni
    Giancarlo Solaini
    Molecular and Cellular Biochemistry, 2000, 215 : 31 - 38
  • [6] Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor
    Cleary, Joanne
    Johnson, Kathryn M.
    Opipari, Anthony W.
    Glick, Gary D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (06) : 1667 - 1670
  • [7] Cysteine 202 in Cyclophilin D inhibits the cardiac mitochondrial F1F0-ATPase
    Casin, Kevin
    Murphy, Tish
    Amanakis, Georgios
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2022, 173 : S65 - S65
  • [8] Identification and characterization of Arabidopsis thaliana mitochondrial F1F0-ATPase inhibitor factor 1
    Chen, Cuiting
    Meng, Yiqing
    Shopan, Jannat
    Whelan, James
    Hu, Zhongyuan
    Yang, Jinghua
    Zhang, Mingfang
    JOURNAL OF PLANT PHYSIOLOGY, 2020, 254
  • [9] REGULATORY PROTEINS OF F1F0-ATPASE - ROLE OF ATPASE INHIBITOR
    HASHIMOTO, T
    YOSHIDA, Y
    TAGAWA, K
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 1990, 22 (01) : 27 - 38
  • [10] INHIBITION OF MITOCHONDRIAL F1F0-ATPASE BY PGBX, A DERIVATIVE OF PROSTAGLANDIN-B1
    KREUTTER, DK
    DEVLIN, TM
    FEDERATION PROCEEDINGS, 1980, 39 (06) : 2151 - 2151
12345